

Statins and Progression of Coronary Atherosclerosis in Melanoma Patients Treated with Immune Checkpoint Inhibitors (SOCRATES): Progress and Updates

Tan S^{1,2}, McArthur G³, and Nicholls SJ^{1,2}, on behalf of the SOCRATES Investigators

¹ Victorian Heart Institute, Melbourne, Australia

² Monash Health Heart, Monash Health, Melbourne, Victoria

³ Victorian Comprehensive Care Centre, Melbourne, Australia



Background


Immune checkpoint inhibitors (ICI) are widely used in the treatment of advanced and resected melanoma but are associated with increased long-term risk of myocardial infarction in melanoma survivorship.

Aims and Methods

SOCRATES is an MRFF-funded prospective observational study of ICI-treated melanoma patients and survivors aged ≥40 years that aims to determine the:

- 1) Natural history of coronary atherosclerosis following ICI therapy
- 2) Cardiovascular (CV) risk profile of melanoma patients
- 3) Impact of statin therapy on CV risk

Participants will undergo CV risk assessment and computed tomography coronary angiography (CTCA) at baseline and 18 months. Abnormal findings detected during the study will be treated as per standard of care.




Primary endpoint:

Progression of non-calcified coronary plaque on CTCA in 18 months (*example illustrated by red arrows below*)




Target recruitment: 130 participants

Results to Date




6 sites open



24 patients enrolled

Patient Reported History	
Median age, years	62 [55, 71]
Hypertension	6 (25%)
Dyslipidaemia	0
Type 2 diabetes mellitus	0
Smoking	
Active smoking	4 (17%)
Previous smoking	8 (33%)
Median body mass index, kg/m ²	27.7 [25.8, 33.2]
Predicted 5-Year Risk of CV events	
Low (<5%)	14 (58%)
Intermediate (5-9%)	6 (25%)
High (≥10%)	4 (17%)



Conclusion

SOCRATES is a novel Australian Cardio-Oncology study that will provide insight into the incidence of CV disease and risk among melanoma patients and survivors treated with ICIs. The results of this study will guide CV risk reduction among the growing number of melanoma survivors in Australia.

SOCRATES is currently open for recruitment and looking for interested sites across Australia. A tele-trial option is also available. For more information, please contact Socrates.Study@monash.edu or Sean.Tan@monash.edu.